{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:39:33Z","timestamp":1787495973657,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Fibrodysplasia ossificans progressiva (FOP) is an extremely rare and severely disabling autosomal dominant disease that is yet to be clearly understood. The purpose of this review is to present recent literature on pathophysiology, clinical features, diagnosis and treatment of FOP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      FOP is characterized by congenital great toe deformity and progressive heterotopic ossifications in connective tissue. Heterotopic ossifications occur after painful flare-ups that can arise spontaneously or can be triggered by minor trauma. Each flare-up ultimately causes restriction of related-joint, and along with the others eventually leads to immobility. Death is usually caused by pulmonary complications because of chest wall involvement. The causative gene of FOP is activin A receptor type 1 (\n                      <jats:italic toggle=\"yes\">ACVR1<\/jats:italic>\n                      ), a bone morphogenetic protein-signalling component, which normally acts to inhibit osteoblastogenesis. The treatment of FOP is still preventive and supportive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Although there are still gaps in the underlying mechanism of FOP, effective treatment options, such as potential pharmacologic targets and cell-based therapies are promising for the future. Some of these were tested without a clinical trial setting, and are currently in the process of evidence-based research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000000802","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T17:36:23Z","timestamp":1563730583000},"page":"716-722","source":"Crossref","is-referenced-by-count":12,"title":["Fibrodysplasia ossificans progressiva: lessons learned from a rare disease"],"prefix":"10.1097","volume":"31","author":[{"given":"Gulseren","family":"Akyuz","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kardelen","family":"Gencer-Atalay","sequence":"additional","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Marmara University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Ata","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Marmara University School of Medicine, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13023-018-0761-2","article-title":"Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases","volume":"13","author":"Stein","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.bone.2017.08.032","article-title":"The FOP Connection Registry: design of an international patient-sponsored registry for fibrodysplasia ossificans progressiva","volume":"109","author":"Mantick","year":"2018","journal-title":"Bone"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/bcp.13777","article-title":"Special considerations for clinical trials in fibrodysplasia ossificans progressiva (FOP)","volume":"85","author":"Hsiao","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5582\/irdr.2017.01055","article-title":"Fibrodysplasia ossificans progressiva: basic understanding and experimental models","volume":"6","author":"Qi","year":"2017","journal-title":"Intractable Rare Dis Res"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bone.2017.06.011","article-title":"The obligatory role of activin A in the formation of heterotopic bone in fibrodysplasia ossificans progressiva","volume":"109","author":"Alessi Wolken","year":"2018","journal-title":"Bone"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1002\/jbmr.3235","article-title":"The expansion of heterotopic bone in fibrodysplasia ossificans progressiva is activin A-dependent","volume":"32","author":"Upadhyay","year":"2017","journal-title":"J Bone Miner Res"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3803\/EnM.2018.33.3.331","article-title":"Recent topics in fibrodysplasia ossificans progressiva","volume":"33","author":"Katagiri","year":"2018","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.bone.2017.11.014","article-title":"Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Wang","year":"2018","journal-title":"Bone"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13287-018-1107-7","article-title":"BMP-dependent, injury-induced stem cell niche as a mechanism of heterotopic ossification","volume":"10","author":"Kan","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00256-018-2889-5","article-title":"Fibrodysplasia ossificans progressiva: a current review of imaging findings","volume":"47","author":"Bauer","year":"2018","journal-title":"Skeletal Radiol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.bone.2017.06.009","article-title":"Joint-specific risk of impaired function in fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Pignolo","year":"2018","journal-title":"Bone"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bone.2017.09.014","article-title":"Clinical staging of fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Pignolo","year":"2018","journal-title":"Bone"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"686","DOI":"10.2106\/JBJS.I.00705","article-title":"Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva","volume":"92","author":"Kaplan","year":"2010","journal-title":"J Bone Joint Surg Am"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bone.2017.04.015","article-title":"A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP)","volume":"101","author":"Kaplan","year":"2017","journal-title":"Bone"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.bone.2017.06.005","article-title":"Longitudinal patient-reported mobility assessment in fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Kaplan","year":"2018","journal-title":"Bone"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bone.2017.09.016","article-title":"Cartilage-derived retinoic acid-sensitive protein (CD-RAP): a stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Lindborg","year":"2018","journal-title":"Bone"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bone.2017.08.011","article-title":"Imaging assessment of fibrodysplasia ossificans progressiva: qualitative, quantitative and questionable","volume":"109","author":"Al Mukaddam","year":"2018","journal-title":"Bone"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2019.03.009","article-title":"Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: an [(18)F]NaF PET\/CT study","volume":"124","author":"Botman","year":"2019","journal-title":"Bone"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-017-0659-4","article-title":"International physician survey on management of FOP: a modified Delphi study","volume":"12","author":"Di Rocco","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"e1295","DOI":"10.1542\/peds.2007-1980","article-title":"Early diagnosis of fibrodysplasia ossificans progressiva","volume":"121","author":"Kaplan","year":"2008","journal-title":"Pediatrics"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2147\/TACG.S51064","article-title":"Progressive osseous heteroplasia: diagnosis, treatment, and prognosis","volume":"8","author":"Pignolo","year":"2015","journal-title":"Appl Clin Genet"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/jbmr.3341","article-title":"Palovarotene inhibits osteochondroma formation in a mouse model of multiple hereditary exostoses","volume":"33","author":"Inubushi","year":"2018","journal-title":"J Bone Miner Res"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/bcp.13823","article-title":"Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva","volume":"85","author":"Wentworth","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2017.08.023","article-title":"Mast cell inhibition as a therapeutic approach in fibrodysplasia ossificans progressiva (FOP)","volume":"109","author":"Brennan","year":"2018","journal-title":"Bone"},{"key":"R25-20230918","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00296-018-4179-x","article-title":"Challenges in the treatment of fibrodysplasia ossificans progressiva","volume":"39","author":"Gencer-Atalay","year":"2019","journal-title":"Rheumatol Int"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00774-015-0701-3","article-title":"Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice","volume":"34","author":"Kawao","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"pii: E989","DOI":"10.3390\/ijms19040989","article-title":"The horizon of a therapy for rare genetic diseases: a \u2018druggable\u2019 future for fibrodysplasia ossificans progressiva","volume":"19","author":"Cappato","year":"2018","journal-title":"Int J Mol Sci"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.stemcr.2018.10.007","article-title":"An mTOR signaling modulator suppressed heterotopic ossification of fibrodysplasia ossificans progressiva","volume":"11","author":"Hino","year":"2018","journal-title":"Stem Cell Rep"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acschembio.8b01020","article-title":"Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors","volume":"14","author":"Reinecke","year":"2019","journal-title":"ACS Chem Biol"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1248\/cpb.c18-00598","article-title":"Bis-heteroaryl pyrazoles: identification of orally bioavailable inhibitors of activin receptor-like kinase-2 (R206H)","volume":"67","author":"Sekimata","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/978-1-4939-8651-4_2","article-title":"An overview of recent advances and clinical applications of exon skipping and splice modulation for muscular dystrophy and various genetic diseases","volume":"1828","author":"Rodrigues","year":"2018","journal-title":"Methods Mol Biol"},{"key":"R32-20230918","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.40814.021","article-title":"Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity","author":"Lees-Shepard","year":"2018","journal-title":"Elife"},{"key":"R33-20230918","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43928","article-title":"Response to comment on \u2019Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity\u2019","volume":"8","author":"Goldhamer","year":"2019","journal-title":"Elife"},{"key":"R34-20230918","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bone.2017.12.011","article-title":"Acute and chronic rapamycin use in patients with fibrodysplasia ossificans progressiva: a report of two cases","volume":"109","author":"Kaplan","year":"2018","journal-title":"Bone"},{"key":"R35-20230918","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bone.2017.07.019","article-title":"Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases","volume":"109","author":"Kaplan","year":"2018","journal-title":"Bone"},{"key":"R36-20230918","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.coph.2018.03.007","article-title":"Acquired and congenital forms of heterotopic ossification: new pathogenic insights and therapeutic opportunities","volume":"40","author":"Pacifici","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"R37-20230918","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5582\/irdr.2018.01095","article-title":"Propranolol and ascorbic acid in control of fibrodysplasia ossificans progressiva flare-ups due to accidental falls","volume":"8","author":"Palhares","year":"2019","journal-title":"Intractable Rare Dis Res"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T22:24:03Z","timestamp":1694989443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000802","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}